The National Center for Research Resources at the National Institutes of Health announced today that Rockefeller University has been awarded one of the first Clinical and Translational Science Awards (CTSA), a component of the NIH Roadmap designed to transform clinical and translational research so that new treatments can be developed more efficiently and delivered more quickly to patients. The CTSA program will support 12 research institutions around the country over a funding period of four years and nine months. Rockefeller University has established a new Center for Clinical and Translational Science in conjunction with its award, which is more than $45 million over the funding period.
"We are extremely pleased that the NIH has awarded a CTSA to Rockefeller University," says university President Paul Nurse. "The medical and translational studies conducted at Rockefeller are an integral part of our commitment to science for the benefit of humanity, and this award will allow us to build even further on our strong programs."
"This prestigious award will provide vital resources to enhance our infrastructure to help both basic and clinical investigators translate their scientific discoveries into improved health for the public," says Barry Coller, David Rockefeller Professor and physician-in-chief of the Rockefeller University Hospital. "Clinical and translational science is a multidisciplinary team effort in which research nurses, bioethicists, bionutritionists, biostatisticians, research pharmacists, experts in regulatory issues, and others work with the clinical and basic investigators to convert their ideas into a study involving humans."
The Center for Clinical and Translational Science will be directed by Coller and James Krueger, professor and head of the Laboratory for Investigative Dermatology at Rockefeller and medical director of the Rockefeller University Hospital. The Center will bring together translational researchers at R
Contact: Joseph Bonner